Aeglea BioTherapeutics, Inc.

Historical 13F Holders

Symbol
SYRE
CUSIP
00773J202
All holders as of
Q3 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 00773J202 since 12/18/2024, largest first.

Filer % of Class Filed
Fairmount Funds Management LLC 13D/A
10.0% 10/9/2026
Event 10/7/2026
BlackRock, Inc. 13G/A 6.6% 7/16/2025
Event 6/30/2025
Paradigm Biocapital Advisors LP 13G
5.1% 10/1/2026
Event 9/24/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Perceptive Advisors LLC 13G/A
4.9% 8/14/2026
Event 6/30/2026
RTW Investments, LP 13G/A
4.8% 8/14/2026
Event 6/30/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A
4.6% 2/14/2025
Event 12/31/2024
Tang Capital Management LLC 13G/A
2.4% 2/17/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 287 101 M $9.00B
2026 Q2 268 95.8 M $8.52B
2026 Q1 201 82.7 M $4.16B
2025 Q4 155 81.0 M $2.60B
2025 Q3 139 64.3 M $1.08B
2025 Q2 132 63.6 M $953M
2025 Q1 132 62.1 M $1.00B
2024 Q4 133 59.9 M $1.39B
2024 Q3 121 51.4 M $1.51B
2024 Q2 109 50.4 M $1.18B
2024 Q1 103 31.6 M $1.20B
2023 Q4 55 28.0 M $601M
2023 Q3 28 3.26 M $39.9M